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Abstract
Background: Trabectedin is an antineoplastic agent used for patients with soft tissue sarcoma (STS) who fail
standard-of-care treatment. Real-world data of its performance is scarce. This study evaluates the safety and
effectiveness of trabectedin for patients with advanced STS who were treated at a high-volume sarcoma center.
Methods: A retrospective chart review was performed on 77 patients treated with trabectedin (24 h infusion q3w)
between 01/2005 and 05/2014. Data regarding safety, objective radiological response, progression-free and overall
survival were analyzed.
Results: Median age at treatment onset was 52y [interquartile range (IQR): 45-61y]. Tumors included leiomyosarcoma
(41.6 %), liposarcoma (18.2 %), and synovial sarcoma (13 %). Trabectedin was provided as≥ third-line chemotherapy in
71.4 %. Median number of cycles was 2 (range: 1–17). Dose reduction and treatment delays occurred in 19.5 and
40.3 %, respectively. Toxicities occurred in 78 %, primarily for neutropenia or elevated liver enzymes. Two patients
died secondary to trabectedin-induced rhabdomyolysis. Treatment was discontinued because of disease progression
(84.7 %), toxicity (10 %), and patient preference (5 %). Partial response or stable disease occurred in 14.1 and 33.8 %,
respectively, while 52.1 % developed progressive disease. Median progression-free survival was 1.3 m (IQR: 0.7–3.5 m)
and was significantly higher in patients lacking severe toxicities or progressive disease. Median overall survival
was 6.7 m (IQR: 2.3–12.7 m) and was significantly higher in patients with leiomyosarcoma or liposarcoma relative
to other histologies.
Conclusions: Trabectedin has an acceptable safety profile as an anti-tumor agent. Our data further suggest there
may be some benefit in using trabectedin particularly in patients with leiomyo- or liposarcoma who failed
standard-of-care agents.
Background
Soft tissue sarcomas (STS) are rare solid cancers of
mesenchymal cell origin accounting for <1 % of adult
cancers [1]. Considerable heterogeneity exists with over
50 histologic types of STS, each with distinct clinical
behaviour. Despite this heterogeneity, adult patients
with advanced STS are generally treated similarly with
palliative-intent chemotherapy. Few agents have known
anti-tumor activity in advanced STS, but generally pro-
vide limited benefits in survival outcome. Guidelines
recommend anthracycline-based chemotherapy as first-
line treatment for most advanced STS [2, 3] with a
26 % response rate [4]. Another drug used as first-line
treatment is ifosfamide, which with or without doxo-
rubicin offers a response rate of ~25 % [5]. Treatment
options for patients who fail first-line treatment include
gemcitabine/docetaxel [3], but additional agents are scarce.
Trabectedin is the synthetic version of an anti-cancer
alkaloid agent originally isolated from the Caribbean sea
squirt Ecteinascidia turbinate [6]. Trabectedin covalently
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binds to the DNA minor groove at guanine nucleotides
of specific sequences to inhibit gene activation and re-
pair mechanisms and induce lethal DNA double-strand
breaks that ultimately lead to cell cycle arrest [7].
Additionally, recent studies suggest pleiotropic proper-
ties [8–11]. Trabectedin selectively targets macrophages
and down-regulates the production of pro-inflammatory
mediators, changing the tumor microenvironment and
contributing to anti-cancer activity [8–10]. Trabectedin
also promotes cancer cell differentiation, specifically in
myxoid liposarcoma by modulating the transcription of
genes crucial for adipocytic differentiation [11].
Trabectedin has shown efficacy as salvage chemother-
apy in patients with advanced STS in three phase II
trials [12–14], chemotherapy-naive patients with unre-
sectable advanced disease [15], and in compassionate
use programs [16–18]. An open-label, randomized, phase II
study evaluated two regimens in patients with unresectable
advanced or metastatic liposarcoma or leiomyosarcoma
[19]. This study established that trabectedin (1.5 mg/m2
given as a 24-h intravenous infusion q3w) provided signifi-
cantly better disease control over weekly 0.58 mg/m2 by
improving time to progression (TTP) and progression-free
survival (PFS). In 2007, based on these results, trabectedin
was approved in several countries for use in STS patients
who fail standard treatments or are unsuited to receive
first-line agents [20, 21].
The effectiveness and safety profile of trabectedin in
the aforementioned studies may differ from that of real
clinical settings as patients typically go through rigorous
enrolment processes before entering clinical trials. Insti-
tutional case series provide a suitable means to obtain
real-world data. Therefore, our study aimed to evaluate
the safety and effectiveness of trabectedin in patients
with inoperable or recurrent STS treated at a high-
volume academic sarcoma center in North America.
Methods
Study design
Research ethics board approval at Mount Sinai Hos-
pital (MSH), Toronto, ON, Canada was obtained in order
to identify patients treated with trabectedin from the Uni-
versity of Toronto Sarcoma Group’s medical oncology and
pharmacology database. Informed consent was obtained
in order to include patients into the database. A retro-
spective chart review was performed from medical records
of patients who initiated treatment between 01/01/2005
and 05/30/2014. Inclusion criteria included ≥18 years
old (y); histologically confirmed STS; patients with lo-
cally advanced, metastatic, inoperable, recurrent or
disease progression after first-line treatment; and at
least one treatment cycle. Patients with gastrointestinal
stromal tumors were excluded.
Data collection
Data was extracted by one author (FAA) and 10 % of
data was independently corroborated by two additional
authors (AJC and MEB). Extracted data included patient
demographics and medical history, STS details, pre-
trabectedin treatment information, trabectedin infor-
mation, post-trabectedin treatment information and
follow-up information.
Clinical practice
The University of Toronto Sarcoma Group treats pa-
tients at both Mount Sinai Hospital and Princess
Margaret Cancer Centre (PM), two high-volume adult
sarcoma centres for the province of Ontario. Tumor
specimens were classified according to the World Health
Organization (WHO) system by an expert soft tissue
pathologist (BCD). Patients are generally referred from
regional health centres for multidisciplinary management.
To be eligible for treatment patients had to meet the fol-
lowing criteria: ≥18y, biopsy-proven STS, documented
unresectable advanced or metastatic tumor, either failure
or intolerance to doxorubicin and/or ifosfamide, currently
not receiving anti-cancer treatment, Eastern Cooperative
Oncology Group (ECOG) performance status ≤1; ad-
equate bone marrow reserve (neutrophils >1500/mm3 and
platelets >100,000/mm3); adequate renal function (serum
creatinine <120 μmol/L or calculated creatinine clearance
by Cockroft method >60 mL/min); and adequate hepatic
function (bilirubin >30 μmol/L, aspartate aminotrans-
ferase (AST) and alanine transaminase (ALT) T <1.5U/
L or <2.5U/L if liver metastases, alkaline phosphat-
ase (ALP) <2.5U/L and albumin >25 g/L). Contraindi-
cations included known history of hypersensitivity to
trabectedin or its components, active serious and/or
uncontrolled infection, left ventricular ejection fraction
below lower normal limit, concomitant live vaccines,
creatine kinase (CK) > 2.5x upper normal limit, ele-
vated bilirubin and breast feeding.
Trabectedin was generally given at the recommended
starting dose (1.5 mg/m2) as a 24-h continuous intravenous
infusion q3w. Trabectedin was administered via a portable
infusion pump that enabled outpatient treatment. Before
each cycle patients were assessed to confirm adequate
renal, hepatic and bone marrow reserve function as well as
overall performance status. Anti-emetic prophylaxis with
corticosteroids (20 mg of dexamethasone intravenously
administered 30 min pre-trabectedin) was provided. Dose
reductions (20 % intervals) were made in the event of toxic-
ities occurring during the previous cycle. Once the toxicity
resolved the dose was readjusted at the discretion of the
medical oncologist. Dose adaptations were similar to those
applied in previously published protocols [12, 14]. There
were no pre-defined limits to the number of cycles there-
fore patients with non-progressive disease and no adverse
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events continued receiving treatment until progression,
grade 4 toxicities, and/or patient preference. Response to
treatment was assessed every two cycles by CT scans, which
were reviewed by the treating medical oncologist.
Classifications
Toxicity was retrospectively assessed using the Common
Terminology Criteria for Adverse Events (CTCAE) v4.03
classification [22]. Because of the study’s retrospective na-
ture, only hematological and biochemical results could be
assessed by toxicity scale while clinical adverse events were
only described. Best response to treatment was determined
by two authors (FAA and MEB) who retrospectively
reviewed CT scans and used Response Evaluation Criteria
in Solid Tumors (RECIST) v.1.1 to categorize the response
as either complete remission (CR), partial remission (PR),
stable disease (SD) or progressive disease (PD) [23].
Statistical analysis
Statistical analyses were performed using SPSS 20 (IBM,
Armonk, NY, USA). Data were expressed as median with
the interquartile range (IQR) and percentage, unless
otherwise specified. Survival analyses were conducted by
Kaplan-Meier method and compared with log-rank test.
PFS was calculated from the date of first dose of trabec-
tedin to the date of disease progression as documented
on CT scan. Patients who only received one cycle of tra-
bectedin or died before their first on-treatment CT scan
were excluded from PFS analysis. Patients were censored
at time of death or last follow-up at MSH/PM, whichever
occurred first. Overall survival (OS) was calculated from
the date of first dose of trabectedin to the date of death
or last follow-up at MSH/PM, whichever occurred first.
The cut-off date for follow-up in this study was March
31, 2015. Statistical significance was set at p-value <0.05.
Results
Patient and tumor characteristics
A total of 77 patients were treated with trabectedin for
unresectable advanced or metastatic STS (Table 1). Pa-
tients had a median age of 52y (IQR: 45–61y) and were
predominately female (62.3 %). Overall patients had a
good performance status before treatment (97.4 %). The
majority of patients (57.1 %) had at least one comorbidity
of which hypertension (n = 13), hypothyroidism (n = 7),
diabetes mellitus (n = 6), depression (n = 6), and smoking
(n = 6) were the most common. Nine patients (11.7 %)
had a prior history of cancer including bladder (n = 3),
breast (n = 2), thyroid (n = 2), and lymphoma (n = 2).
The most common STSs included leiomyosarcoma
(41.6 %), liposarcoma (18.2 %), and synovial sarcoma
(13 %). Approximately 27 % of patients had a variety of
rare histologies (“other sarcoma”), which included
spindle cell sarcoma, fibrosarcoma, clear cell sarcoma,
Table 1 Patient and tumour characteristics at time of starting
trabectedin
Variable N (%)
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high-grade pleomorphic undifferentiated sarcoma and
rhabdomyosarcoma. Of patients who had information
available, the majority of tumors were high grade
(55.1 %).
Tumors were primarily localized in in the torso (66.2 %).
The most common sites of primary disease were uterus
(27.3 %), retroperitoneum (16.9 %), and abdomen/pelvis
(14.3 %). At the time of starting trabectedin 51 (66.2 %) pa-
tients had one or more metastasis. Patients had metastasis
with the following number of sites involved: one (52.6 %),
two (33.3 %), and three or more (14 %). Anatomical distri-
bution of metastasis was as follows: lung (80.7 %), liver
(26.3 %), abdomen/pelvis (22.8 %), and bone (24.6 %)
Treatment before trabectedin
All 77 patients received first-line chemotherapy before
staring trabectedin. The majority of patients (71.4 %) re-
ceived at least two lines of chemotherapy before starting
trabectedin. Prior to trabectedin, 11 patients underwent
radiation therapy with the following intent: neoadjuvant
(9.1 %), adjuvant (36.7 %), and palliative (54.5 %). A total
of 64 (83.1 %) patients had surgery for their primary
tumor prior to starting trabectedin while the remaining
13 patients had inoperable tumors. Margin status after
surgery for patients’ primary STS was as follows: R0
(76.6 %), R1 (20.3 %), and R2 (3.1 %). Local recurrence
was diagnosed in 20 (31.3 %) patients. Distribution of
site of local recurrence was as follows: abdomen/pelvis
(50 %), thorax (20 %), retroperitoneum (15 %), and ex-
tremity (5 %). Twenty-three patients underwent additional
surgery including positive margin excision (17.4 %), local
recurrence excision (17.4 %), and metastectomy (65.2 %).
Trabectedin was provided for patients with recurrent
metastatic (57.1 %), locally recurrent (16.9 %), inoperable
primary (16.9 %), and both locally recurrent and meta-
static (9.1 %) tumours.
Trabectedin treatment characteristics
Median time from diagnosis to start of trabectedin was
22.4 months (m) (IQR: 13.3–44.9 m). Median number of
cycles of trabectedin was 2 (range: 1-17) during a me-
dian time of 1.5 m (range: 0.3–16 m). Trabectedin was
primarily provided as second- and third-line chemother-
apy in 28.6 % and 44.2 % patients, respectively; while the
remaining 27.3 % received it as ≥4-line treatment. Of the
77 patients, 2 patients were started on trabectedin after
developing severe toxicities with other lines of chemo-
therapy while the remaining 75 patients received treat-
ment due to disease progression.
The majority of patients (96.1 %) started treatment at
a dose of 1.5 mg/m2. Three patients started treatment at
1.2 mg/m2 because they were considered frail; two of
these patients eventually had their dose increased to
1.5 mg/m2 because they tolerated treatment. Frequency
and reasons for dosage and schedule modifications are
depicted in Fig. 1. A total of 15 patients (19.5 %) re-
quired dose reductions primarily owing to low absolute
neutrophil count (ANC) (40 %), followed by hepatotox-
icity (26.7 %) and clinical reasons (20 %) (Fig. 1a). In the
majority of cases, patients required a single dose reduc-
tion (86.7 %), but dosage was generally readjusted to
normal (66.7 %). A total of 31 (40.3 %) patients had
treatment delays primarily because of low ANC (61.3 %),
catheter problems (12.9 %), and personal reasons
(12.9 %) (Fig. 1b). Number of treatment delays per pa-
tient was as follows: one (80.6 %), two (16.1 %), and
three (3.2 %). Trabectedin therapy was discontinued in
72 patients (93.5 %) because of disease progression
(84.7 %), severe adverse events (9.7 %), and patient deci-
sion (5.6 %) (Fig. 1c). Currently five patients are under-
going treatment with trabectedin.
Trabectedin-related toxicities
A total of 150 hematological and/or biochemical toxic-
ities occurred in 60 patients (Table 2). The median num-
ber of hematological and/or biochemical toxicities per
patient was 2 (IQR: 1-3). The most common toxicities
included low ANC (29.3 %) and elevated liver enzymes
(26 %). Events of severe toxicity (CTCAE grade ≥3), pri-
marily occurred because of elevation of liver enzymes
(18.7 %), low ANC (12.7 %), and elevated CK (3.3 %). A
total of 25 clinical adverse events occurred with the
following distribution: nausea/vomiting (n = 18), fatigue
(n = 5), diarrhea (n = 1), and leg edema (n = 1).
Deaths attributed to drug-related events were reported
in two patients both of which were due to rhabdomyoly-
sis. One patient with recurrent metastatic poorly differ-
entiated leiomyosarcoma in the abdomen developed
elevated CK after two cycles. The patient was admitted
for rhabdomyolysis and treated, but died from acute
tubular necrosis. Another patient with an inoperable
retroperitoneal grade III malignant fibrous histiocytoma
died after three cycles of trabectedin. The patient pre-
sented with severe bilateral lower limb pain and edema
and blood work suggested ongoing rhabdomyolysis and
acute renal failure. Despite treatment, the CK continued to
increase, reaching 18,400U/L, until the patient eventually
developed anuria and died secondary to acute renal failure.
Table 1 Patient and tumour characteristics at time of starting
trabectedin (Continued)
Extent of tumour
Inoperable primary tumour 13 (16.9)
Locally recurrent 13 (16.9)
Recurrent metastatic tumour 44 (57.1)
Locally recurrent and metastasis 7 (9.1)
ECOG Eastern Cooperative Oncology Group
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Effectiveness
Seventy-one were assessed for effectiveness. Six patients
were excluded because they did not have on-treatment
CT scans at the study cut-off date: three patients
stopped treatment after cycle 1 for personal reasons,
one patient had only one cycle, and two patients had
early, severe toxicities requiring treatment suspension.
Figure 2 illustrates best response to trabectedin as mea-
sured by RECIST. While CR was not observed in any
patient, partial PR and SD were recorded as best response
in 10 (14.1 %) and 24 (33.8 %) patients, respectively. The
remaining 37 (52.1 %) patients showed PD. Figure 3 de-
picts the distribution of best type of response to trabecte-
din according to tumor histology. Trabectedin tended to
induce PR in patients with liposarcoma (21.4 %) and leio-
myosarcoma (12.5 %) (Fig. 4).
The median PFS was 1.3 m (IQR: 0.7–3.5 m). Fig. 5a-e
depicts PFS stratified by factors with potential impact on
outcome. PFS was significantly higher in patients who
had grade <3 toxicities relative to those with grade ≥3
toxicities (1 m versus 2 m, p = 0.02). PFS was also signifi-
cantly higher in patients who had PR or SD relative to
those with PD (PR: 5 m versus PD: 1 m, p < 0.0001 and
SD: 2 m versus PD: 1 m, p < 0.0001). Trabectedin did
not induce significant improvements in PFS depending
on histology, extent of tumor at presentation, or current
number of line of chemotherapy. The median follow-up
time was 6.6 m (IQR: 2.3–12.7 m). The median OS for
this cohort was 6.7 m (IQR: 2.3-12.7 m). Fig. 5f-j depicts
OS stratified by factors with potential impact on out-
come. Patients with leiomyosarcoma or liposarcoma had
significantly higher OS relative to other types (leioymyo-
sarcoma: 12.2 m versus others: 3.7 m, p < 0.0001 and
liposarcoma: 10.5 m versus others: 3.7 m, p = 0.002). OS
was significantly higher in patients who had PR relative
to those with PD (PR: 16 m versus PD: 6 m, p = 0.003).
OS did not improve depending on extent of tumor at
presentation, current number of line of chemotherapy,
Fig. 1 Trabectedin dose and schedule modifications. a Reasons for
dose reductions (n = 15 patients, 19.5 %). b Reasons for schedule delay
(n = 31, 40.3 %). Number of delayed cycles per patient: one (n = 25,
80.7 %), two (n = 5, 16.1 %) and three (n = 1, 3.2 %). c Reasons to
discontinue trabectedin (n = 72, 93.5 %). Abbreviations: ANC, absolute
neutrophil count; CK, creatine kinase
Table 2 Trabectedin-related toxicities











Anemia 8 (10.4) 3 (3.9) 6 (7.8) - -
Low ANC 1 (1.3) 24 (32.4) 15 (20.3) 4 (5.2) -
Thrombocytopenia
5 (6.5) - 1 (1.3) 2 (2.6) -
Lymphoenia 1 (1.3) - 1 (1.3) - -
Febrile
neutropenia
- - 2 (2.6) - -
Biochemical
Elevated ALP 12 (15.6) 2 (2.6) 4 (5.2) 2 (2.6) -
Elevated GGT 10 (12.9) 2 (2.6) 5 (6.5) 2 (2.6) -
Elevated CK 4 (5.2) 1 (1.3) 1 (1.3) 2 (2.6) 2 (2.6)
Elevated AST 3 (3.9) 2 (2.6) 5 (6.5) 2 (2.6) -
Elevated ALT 6 (7.8) 1 (1.3) 5 (6.5) 3 (3.9) -
Elevated bilirubin - - 1 (1.3) - -
ALP alkaline phosphatase, ALT alanine transaminase, ANC absolute neutrophil
count, AST aspartate aminotransferase, CK creatine kinase, GGT
gamma-glutamyl transferase
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Fig. 2 Best response to trabectedin in 71 patients with soft tissue sarcoma. Waterfall plots depict change from baseline in sum of longest diameters of
target lesions for each patient according to tumor histology (a) and grade (b). Six patients were excluded from this analysis because CTs were not
performed: 3 stopped treatment after cycle 1 for personal reasons, 1 recently started treatment and 2 had early toxicities requiring treatment suspension.
Cut-off levels were based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions [23]
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or severity of toxicity. At the end of the follow-up
period, 54 (70.1 %) patients had died of their disease
(n = 52) or trabectedin-related causes (n = 2). Twenty-
three patients are alive and undergoing the following
treatments: other chemotherapies (n = 9), palliative
care (n = 6), trabectedin (n = 5), and targeted therapies
(n = 3).
Discussion
This study assessed the safety and effectiveness of tra-
bectedin in a ‘real-world’ setting in patients with ad-
vanced STS. Between 2005 and 2014, our high-volume
adult sarcoma centre treated 77 patients with trabecte-
din, the largest retrospectively published cohort of pa-
tients in North America to date. Our cohort resembles
that of other larger studies in terms of patient and tumor
characteristics [13, 24, 25]. Our results confirm that
trabectedin is a well-tolerated agent that appears to in-
duce some response in patients with advanced STS who
previously failed standard-of-care chemotherapy. Trabecte-
din has a manageable safety profile with common toxicities
including reversible low ANC, anemia, thrombocytopenia
and hepatotoxicity and rare, severe clinical consequences
such as elevated CK and rhabdomyolysis. Cumulative tox-
icities were not observed. At best, trabectedin induced a
PR, particularly in patients with lipo- and leiomyosarcoma.
Patients who had grade ≥3 toxicities and PD had signifi-
cantly worse PFS relative to their counterparts. OS was sig-
nificantly higher in patients with leiomyo- or liposarcoma
relative to their counterparts. Given that our treatment in-
clusion criteria were less restrictive than those of clinical
studies, our study depicts how trabectedin acts in a real
clinical setting.
Trabectedin treatment in our cohort was reasonably
well tolerated with an overall safety profile consistent
with that of previous studies. As previously reported, the
most common toxicities included self-limiting low ANC
and elevated liver enzymes [25, 26]. Neutropenia was the
most common drug-related toxicity and its incidence
and severity is particularly higher with the dosing sched-
ule used by our group [25]. Neutropenia followed a pre-
dictable and reversible course and was rarely associated
with fever (1.9 %) or infection (1.8 %) as also noted in
our cohort [25, 27]. Elevated liver enzymes occurred
mainly in the first weeks of the first cycle and levels gen-
erally returned to baseline by day one of cycle two [25,
28]. Excluding patients with a known history of active
liver disease and closely monitoring patients provides an
adequate opportunity to adjust treatment. Notably, the
incidence of bilirubin and alkaline phosphatase eleva-
tions was low and was not cumulative as previously re-
ported [25].
In this study, the prevalence of grade ≥3 elevated liver
enzymes and low ANC was within the rates reported in
previous studies (low ANC: 33–61 % and transaminitis:
20–57 %) [12–15, 29, 30]. Despite the frequency of grade
≥3 toxicities, they only accounted for 2.8 % of the rea-
sons why trabectedin was discontinued. Additionally
events requiring in-hospital management affected 10 %
of our patients, which is similar to the rate reported by
other groups (9.4–17 %) [16, 24]. Clinical manifestations
Fig. 3 Distribution of best type of response to trabectedin
according to tumor histology. Best response was assessed using
Response Evaluation Criteria in Solid Tumors (RECIST) (n = 71)
Fig. 4 CT scans of patients who responded to trabectedin. a Patient with recurrent metastatic grade II myxoid liposarcoma encasing the aorta.
Paired axial (1,2) and coronal (3,4) cuts showing a partial response after 16 cycles of trabectedin. b Patient with recurrent poorly differentiated
leiomyosarcoma that metastasized to the liver. Paired axial (1,2) cuts showing a partial response after 2 cycles of trabectedin
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Fig. 5 (See legend on next page.)
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of severe hepatic injury are rare; therefore the changes
observed in liver function tests mainly represent bio-
chemical changes without permanent hepatic injury [25].
Post-treatment liver biopsies showed no evidence of per-
sistent liver histopathological changes attributable to tra-
bectedin [31].
Clinical adverse events were common in our patients.
At least 20 % of patients develop clinical symptoms in-
cluding nausea (64.7 %), fatigue (58.3 %), and vomiting
(40.1 %) [25]. Nausea and vomiting, often associated
with trabectedin, can be mitigated by pre-treating pa-
tients with dexamethasone [32]. Although the mechan-
ism is yet unclear, the protection by dexamethasone
against trabectedin-mediated toxicity may be attributed
to enhanced Mrp2 biliary excretion and increased me-
tabolism by CYP3A1/2 [33]. Notably, the adverse events
commonly induced by cytotoxic chemotherapy or that
are potentially dose-limiting, debilitating, cumulative
and/ or life threatening are rare with trabectedin [25].
Overall trabectedin’s safety profile compares favorably
with that of current standard-of-care agents used against
STS [34].
Dosage and scheduling adjustments were in concord-
ance with those reported by other studies. Dose reduc-
tion was necessary in 19.5 % of patients, which is well
within the rate reported in the literature (14–48 %) [13,
17, 24, 26]. As expected the primarily causes for dose re-
duction were either low ANC or elevated liver enzymes
[13, 26]. Approximately 40 % of our patients required
treatment delays. Other studies have reported lower
rates (27.7–36 %), but continue to find that neutropenia
and increased transaminases are the two main causes
[13, 17, 25]. Treatment discontinuations due to toxicity
was necessary in 9.7 % patients, which is similar to the
rate reported in the literature (8–10.2 %) [17, 25]. The
primary reasons for treatment discontinuance include
disease progression (63 %) [17].
Deaths attributed to drug-related events occurred in
two patients and were attributed to rhabdomyolysis. The
reported death rate is 0.5–1.7 % [17, 24, 25]. Deaths gen-
erally occur during the first two cycles of treatment and
are mainly due to rhabdomyolysis [14, 25, 35]. Less fre-
quently trabectedin causes death by inducing severe
myelosuppression and respiratory failure [17]. Periodic
monitoring of creatine phosphokinase as well as aware-
ness of clinical manifestations is recommended for
timely intervention.
Twenty-three percent of patients in our study re-
ceived ≥6 cycles. In other studies a slightly higher per-
centage of patients (30–34 %) received an equivalent
number of cycles of treatment suggesting an acceptable
toxicity profile that allows prolonged treatment in cer-
tain patients [16, 24]. The number of patients undergo-
ing long-term treatment would have been higher had
they not progressed as trabectedin lacks cumulative
toxicities [16, 24]. In a study that grouped data from 11
French centres, Blay et al reported that among 56 pa-
tients who were not progressing after six cycles, the 40
who continued treatment had a significantly higher PFS
and OS relative to other patients [16]. Certainly these
results must be taken in context of the retrospective na-
ture of that study nevertheless maintenance therapy in pa-
tients with advanced STS is an option worth evaluating.
In our study both the median PFS and OS were on the
lower end of what has been previously reported (PFS:
1.7–3.4 m and OS: 8.9–15.8 m) [12, 14, 15, 18, 36]. Our
lower survival outcomes may be due to the fact that tra-
bectedin was primarily given as a third- or more line of
treatment in the majority of our patients. Other studies
have reported higher survival outcomes because patients
were not as heavily pre-treated as our cohort. In a study
by Le Cesne et al in which only 58.7 % of 885 patients
received trabectedin as a third- or more line of treat-
ment, the median PFS and OS were 4.4 m and 12.2 m,
respectively [24]. In another study where 32 % of the co-
hort received trabectedin as a third or more line of treat-
ment, the median PFS and OS were 3.7 and 8.8 m,
respectively [37].
Trabectedin has the potential to provide clinically
meaningful benefits to a specific subset of STS patients
who have failed standard-of-care treatment particularly
if their tumours are either leiomyo- or liposarcoma. Both
these subtypes of STS had an OS that was significantly
higher relative to patients with other types of STS. This
finding was previously shown in other studies in which
the median OS was 12-16 m [13, 14, 17]. The severity of
toxicities appeared to have an effect on PFS, but not OS
as previously shown [16]. A possible explanation is that
patients who develop severe toxicities after trabectedin
receive a lower number of cycles because trabectedin is
discontinued therefore decreasing their chances of
responding to treatment. Objective radiological response
to treatment as measured by RECIST was also associated
with improved OS. Despite the fact that trabectedin
(See figure on previous page.)
Fig. 5 Trabectedin survival analyses. Kaplan-Meier (KM) survival curves for progression-free survival (PFS) (left column) and overall survival (OS)
(right column) stratified by tumor histology (a, f), extent of tumor at presentation (b, g), line of treatment with trabectedin (c, h), severity of toxicity
(d, i) and best response by RECIST (e, j). Abbreviations: m, months; OS, overall survival; PFS, progression free survival, RECIST, Response Evaluation
Criteria in Solid Tumors
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induced a moderate radiological response (PR and SD)
of 48 %, as previously reported [17, 36], the effect on
tumor burden was enough to significantly improve PFS
and OS. In another study patients who responded to tra-
bectedin (PR or SD) also had a significantly higher PFS
(7.7 m versus 2.1 m, p < 0.0001) and OS (12.1 m versus
5.5 m, p = 0.01) [37].
Conclusion
Trabectedin has an acceptable and manageable safety pro-
file and provides encouraging anti-tumor activity particu-
larly in patients with leiomyo- or liposarcoma who failed
standard-of-care agents. Trabectedin does not develop cu-
mulative toxicity even in patients who receive a high num-
ber of cycles. Response to treatment according to RECIST
criteria was modest, especially in patients with lipo- and
leiomyosarcoma. OS was significantly improved in pa-
tients with leiomyo- or liposarcoma relative to other types
of STS. The clinically meaningful benefits provided by tra-
bectedin are comparable to those previously observed in
clinical trials and other real-world case series. Our data
further support the benefits of trabectedin in patients
with advanced leiomyo- and liposarcoma who have
failed standard-of-care agents.
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